P-1103. In Vitro Activity of Zoliflodacin Against Baseline <i>Neisseria gonorrhoeae</i> Isolates from US Participants in a Global Phase 3 Randomized Controlled Trial

Sarah M. McLeod(Innoviva (United States)), Alison Luckey(Global Antibiotic Research & Development Partnership), Esther Bettiol(Global Antibiotic Research & Development Partnership), Varalakshmi Elango(Global Antibiotic Research & Development Partnership)
Open Forum Infectious Diseases
January 29, 2025
10.1093/ofid/ofae631.1291
Cited by 0

Related Papers

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
|The Lancet|2025|26
2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study
|Open Forum Infectious Diseases|2023|25